FDA Brief

Warning letters Drugs

FDA warning letter to

DuPont Nutrition USA Inc.

High riskIssued Dec 2, 2022Posted Dec 20, 2022Division of Pharmaceutical Quality Operations I

FDA found DuPont released Avicel excipient that failed conductivity limits, citing weak investigations and data integrity lapses.

What happened

FDA inspected the Newark, Delaware plant that makes Avicel, a non-active drug ingredient (an excipient), from November 17 to December 15, 2021. Investigators found about 50 customer complaints from April 2020 to June 2021 that Avicel failed the USP conductivity standard; the conductivity meter probe was encrusted with residue and gave falsely low readings, failing lots had already been shipped, and customers were not told for months. The inspection also found retests that turned failing results into passing ones, backdated laboratory records, use of unreleased microbiological growth media, unverified and unvalidated test methods, and conductivity meters removed without documented change control.

What FDA found

  1. About 50 customer complaints that Avicel failed the conductivity standard were not adequately investigated, and affected batches were shipped and not reported to customers for months.

    FD&C Act 501(a)(2)(B)
  2. Out-of-specification (outside the allowed limit) test results were not fully or promptly investigated, and the probe caked with grime that caused falsely low readings was not traced to other affected lots in good time.

    FD&C Act 501(a)(2)(B)
  3. The conductivity test methods were not properly verified or validated, and a quick in-house method that read much lower than the USP method was approved for production release testing.

    FD&C Act 501(b)
  4. Conductivity meters were removed around 2011 without a documented change control, even though conductivity had been identified as a critical quality parameter.

    FD&C Act 501(a)(2)(B)
  5. Failing pH, conductivity, loss on drying and particle size results were changed to passing by retesting without adequate investigation or justification.

    FD&C Act 501(a)(2)(B)
  6. Laboratory staff backdated the approval on a microbiological media worksheet and used unreleased growth media plates for drug testing, and test records lacked sample weights and instrument references.

    FD&C Act 501(a)(2)(B)

What FDA wants

FDA tells the company to reply in writing within 15 working days with what it has done and will do, including independent assessments and remediation plans for complaint handling, OOS investigations, test method verification and validation, change management and data integrity, plus a retrospective review of invalidated OOS results and released lots. FDA strongly recommends hiring a qualified third-party consultant and says to contact its Drug Shortages Staff immediately if corrective action could disrupt supply.

Who should pay attention

  • drug manufacturers that use Avicel (MCC) as an excipient
  • quality teams at excipient makers and contract testing labs
  • companies that rely on supplier certificates of analysis for release

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk